Supernus Pharmaceuticals (SUPN) : The money flow analysis of Supernus Pharmaceuticals (SUPN) indicates a $1.28 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $2.21 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.73 and so was the total money flow at $0.93 million. The bulls lapped up $0.83 million worth of block trades on upticks. The money flow was $0.83 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Supernus Pharmaceuticals (SUPN), pushing it down by -0.27% for the day. The stock slid $0.06 and traded at $21.97 during the day. Nonetheless, the stock is -0.45% over the previous weeks close.
The company Insiders own 6.1% of Supernus Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -37.68% . Institutional Investors own 98.81% of Supernus Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -35.19%.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (VP, Chief Financial Officer) of Supernus Pharmaceuticals Inc, Patrick Gregory S had sold 3,395 shares worth of $74,690 in a transaction dated July 14, 2016. In this transaction, 3,395 shares were sold at $22 per share.
Supernus Pharmaceuticals (NASDAQ:SUPN): stock was range-bound between the intraday low of $21.7 and the intraday high of $22.09 after having opened at $22.09 on Fridays session. The stock finally closed in the red at $22.09, a loss of -0.27%. The stock remained in the red for the whole trading day. The total traded volume was 315,149 shares. The stock failed to cross $22.09 in Fridays trading. The stocks closing price on Thursday was $22.03.
Supernus Pharmaceuticals (SUPN) : During the past 4 weeks, traders have been relatively bearish on Supernus Pharmaceuticals (SUPN), hence the stock is down -4.81% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.95% relative to the S&P 500. The 4-week change in the price of the stock is -4.93% and the stock has fallen -0.45% in the past 1 week.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.